Trial intelligence / Profile preview

Alkaline phosphatase for prevention of ischemia-reperfusion injury in living donor kidney transplantation

NL-OMON50363Phase 3Active, not recruiting

Sponsor: Vrije University Medical Center
Start: May 2019
Countries: 1

Overview

Phase 3, randomised, double-blind trial in ischemia-reperfusion injury (IRI) and Kidney allograft dysfunction comparing Alkaline phosphatase + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Graft function at 12 months and Safety. Started May 2019; status: active, not recruiting.

Conditions

ischemia-reperfusion injury (IRI)Kidney allograft dysfunction

Beyond the preview

Go deeper on NL-OMON50363.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON50363.